Clin Nucl Med. 2021 Feb 1;46(2):e121-e122. doi: 10.1097/RLU.0000000000003306.
A 58-year-old man with previous melanoma of the left leg underwent whole-body 18F-FDG PET/CT to stage metastatic disease prior to commencing pembrolizumab. Follow-up FDG PET/CT after 3 months of treatment showed partial metabolic response of soft tissue and nodal metastases and diffuse increased thyroid and colonic uptake, suggestive of thyroiditis and colitis. Pembrolizumab was ceased, and a repeat FDG PET/CT scan showed regression of uptake in the thyroid gland and colon, in keeping with resolution of inflammatory change. Immune-related adverse events induced by Immune checkpoint inhibitors, such as pembrolizumab, should be recognized-cessation of treatment often leads to resolution.
一位 58 岁男性，左小腿曾患有黑色素瘤，在开始使用派姆单抗前进行了全身 18F-FDG PET/CT 检查以分期转移疾病。治疗 3 个月后的 FDG PET/CT 随访显示软组织和淋巴结转移的部分代谢反应以及甲状腺和结肠摄取弥漫性增加，提示甲状腺炎和结肠炎。停止使用派姆单抗，重复 FDG PET/CT 扫描显示甲状腺和结肠摄取减少，符合炎症变化的消退。免疫检查点抑制剂（如派姆单抗）引起的免疫相关不良事件应得到识别-停止治疗通常会导致其消退。
